Cargando…

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma

Multiple myeloma (MM) is the second most common hematological cancer and is characterized by genetic features including translocations, chromosomal copy number aberrations, and mutations in key oncogene and tumor suppressor genes. Dysregulation of the tumor suppressor TP53 is important in the pathog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flynt, Erin, Bisht, Kamlesh, Sridharan, Vinidhra, Ortiz, María, Towfic, Fadi, Thakurta, Anjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072230/ https://www.ncbi.nlm.nih.gov/pubmed/31991614 http://dx.doi.org/10.3390/cells9020287

Ejemplares similares

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways
por: Ortiz-Estévez, María, et al.
Publicado: (2021)

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways
por: Karagoz, Kubra, et al.
Publicado: (2022)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
por: Bauer, Michael A., et al.
Publicado: (2020)

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease
por: Mason, Mike J., et al.
Publicado: (2020)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
por: Hao, Suyang, et al.
Publicado: (2017)

Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
por: Feng, Xiangling, et al.
Publicado: (2022)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression
por: Steffens Reinhardt, Luiza, et al.
Publicado: (2023)

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
por: Liu, Enze, et al.
Publicado: (2023)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model
por: Munawar, Umair, et al.
Publicado: (2019)

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
por: Sudha, Parvathi, et al.
Publicado: (2022)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression
por: Murakami, Yuki, et al.
Publicado: (2022)

P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma
por: Khan, Safir Ullah, et al.
Publicado: (2023)

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
por: Chin, M, et al.
Publicado: (2017)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Erratum to “TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma”
Publicado: (2023)

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
por: Pawlyn, C, et al.
Publicado: (2017)

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
por: Walker, Brian A., et al.
Publicado: (2018)

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53
por: Gao, Fan, et al.
Publicado: (2023)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53(abnormal) myeloma cells independently of the p53 pathway
por: Surget, Sylvanie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8paklt31lj7ibv894hrmoq8mso